Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Jonas

Premium
Isis Pharmaceuticals Executive Vice President Jeffrey Jonas has resigned, the company disclosed last week in a filing with the US Securities and Exchange Commission.
 
Jonas joined Isis in early 2007 to lead the company’s clinical and preclinical development efforts, as well as its regulatory affairs. Prior to joining Isis, he served as chief medical officer and executive vice president of Forest Laboratories.
 

Isis did not provide details regarding Jonas’ departure.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.